Metformin Sandoz

Metformin, the active ingredient in Metformin Sandoz, is a biguanide presented as an oral tablet for oral use. It treats type 2 diabetes mellitus by improving blood glucose control in adult patients, decreasing hepatic glucose production and increasing peripheral insulin sensitivity. Metformin Sandoz is supplied in compliance with EU pharmaceutical standards.

GNH USA supplies Metformin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Metformin is an oral antidiabetic agent used in the management of type 2 diabetes mellitus.

Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c levels in adult patients.

Metformin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: transient upset often occurring at treatment initiation. - Diarrhea: loose stools that may improve with dose titration. - Abdominal discomfort: cramping or bloating in the gastrointestinal tract. - Metallic taste: occasional altered taste sensation. - Weight loss: modest reduction in body weight observed in some patients. - Vitamin B12 deficiency: gradual decline with long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening accumulation of lactate, especially in renal impairment. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: marked elevation of liver enzymes or hepatitis. - Hypoglycemia: when combined with other glucose‑lowering agents. - Pancreatitis: inflammation of the pancreas reported infrequently. - Metabolic acidosis: non‑lactic acidosis in susceptible individuals.

When prescribing Metformin Sandoz, clinicians should consider several safety precautions.

Renal function: assess eGFR before initiation and periodically thereafter. Hepatic function: evaluate liver disease as impaired function may increase lactic acidosis risk. Lactic acidosis risk: avoid in patients with conditions predisposing to hypoxia. Vitamin B12 monitoring: long‑term therapy may reduce B12 levels, consider periodic testing. Contraindication in severe renal impairment: do not use if eGFR <30 mL/min/1.73 m². Store at ambient temperature: keep in the original pack, protect from moisture.

Metformin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast media: may precipitate acute renal failure and increase lactic acidosis risk. - Alcohol (excessive): can potentiate lactic acidosis. - Cimetidine: may increase metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function when used together. - Other antidiabetic agents: risk of hypoglycemia when combined.